Glioma Market (US)
Glioma Market Infographic (US)

Glioma Market Overview

A glioma is a central nervous system tumor that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mainly occur in the brain and, rarely, in the spinal cord.

Glioma Epidemiology Insights (2022)

  • The Total Glioma incident cases in the United States were ~19K cases in 2022
  • Glioblastoma contributed to the highest number of glioma cases
  • Around 36% cases were contributed by 60–74 years age group
  • Grade IV accounted for the highest number of incident cases

Glioma Epidemiology Segmentation in the US from 2019 to 2032

  • Total Incident Population
  • Grade-specific Incident Population
  • Type-specific Population of High-grade Glioma
  • Type-specific Population of Low-grade Glioma
  • Age-specific Population
  • Glioma Cases Based on Molecular Alterations

Glioma Market Insight (2022)

The Glioma Market size in the US was valued ~USD 600 million in 2022

Glioma Market Strengths

  • Rise in the aging population
  • Improvement in genomics and proteomics

Glioma Market Opportunities

  • Increasing incidence trend
  • Substantial market opportunity for key players

Glioma Emerging Drugs and Key Companies

  • Regorafenib: Bayer
  • ONC201: Chimerix
  • AV-GBM-1: Aivita Biomedical
  • Enzastaurin (DB-102): Denovo Biopharma
  • DCVax-L: Northwest Therapeutics
  • Ofranergene Obadenovec (VB-111): VBL Therapeutics
  • LAM561 (2-OHOA): Laminar Pharmaceuticals
  • MEDI4736 (durvalumab): MedImmune
  • Tasadenoturev (DNX-2401): DNAtrix
  • ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
  • IGV-001: Imvax
  • SurVaxM: MimiVax
  • Berubicin: CNS Pharmaceuticals
  • GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
  • Lerapolturev + Pembrolizumab: Istari Oncology
  • SONALA-001 + Exablate 2.0 Device: SonALAsense
  • VAL-083 (dianhydrogalactitol): Kintara Therapeutics
  • Pomalidomide: Bristol Myers Squibb
  • MDNA55: Medicenna Therapeutics
  • BMX-001: BioMimetix
  • Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
  • Paxalisib (GDC-0084): Kazia Therapeutics
  • OKN-007: Oblato
  • Temferon: Genenta Science
  • EO2401: Enterome
  • INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
  • Selinexor (KPT-330): Karyopharm Therapeutics
  • VBI-1901: VBI Vaccines
  • NOX-A12 (Olaptesed Pegol): TME Pharma
  • Tovorafenib (DAY101): Day One Biopharmaceuticals
  • Vorasidenib (AG-881): Servier
  • Eflornithine: Orbus Therapeutics
  • TVI-Brain-1: TVAX Biomedical
  • AB-218: AnHeart Therapeutics
  • BGB-290: Beigene
  • Mirdametinib: SpringWorks Therapeutics
  • FT-2102 (Olutasidenib): Forma Therapeutics
  • Vinblastine + Bevacizumab: Hoffmann-La Roche
  • Cobimetinib: Hoffmann-La Roche
  • PEMAZYRE (Pemigatinib): Incyte Corporation
  • VERZENIO (abemaciclib): Eli Lilly, and others